MedTrace Logo

European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial

NCT01087723 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2198

Last updated 2016-02-12

Study results available
· View outcomes & findings →

Summary

To show that the early administration of bivalirudin improves 30 day outcomes when compared to the current standard of care in participants with ST segment elevation acute coronary syndrome (STE-ACS), intended for a primary percutaneous coronary intervention (PCI) management strategy, presenting either via ambulance or to centers where PCI is not performed.

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

Bivalirudin

DRUG

Heparin

Sponsors & Collaborators

  • The Medicines Company

    lead INDUSTRY

Principal Investigators

  • Gabriel Steg, Prof · Executive Committee

  • Christian Hamm, BSc, MD, PhD · International Steering Committee

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2013-08-31
Completion
2014-08-31

Countries

  • Austria
  • Czechia
  • Denmark
  • France
  • Germany
  • Italy
  • Netherlands
  • Poland
  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01087723 on ClinicalTrials.gov